deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01991210

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer

Sponsor: Genentech, Inc.

Conditions Ovarian Cancer
Interventions DNIB0600A PLD
Updated 9 times since 2017 Last updated: Aug 17, 2017 Started: Feb 6, 2014 Primary completion: Aug 17, 2016 Completion: Aug 17, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The primary objective of PFS did not meet pre-specified criteria.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Ovarian Cancer trials with similar outcome

Browse all Ovarian Cancer trials

Listed as NCT01991210, this PHASE2 trial focuses on Ovarian Cancer and remains terminated or withdrawn. Sponsored by Genentech, Inc., it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotCompleted~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotTerminated~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 12 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Sep 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  3. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Barcelona, Spain , Bialystok, Poland , Boston, United States , Covington, United States , Gdansk, Poland , Germantown, United States , Leuven, Belgium , Liège, Belgium , London, Canada and 20 more locations